The electrostability and electrically assisted delivery of an organophosphate pretreatment (physostigmine) across human skin in vitro

Journal of Controlled Release

Volumn 68, Issue 2, 2000, Pages 157-166

  Rowland, Caroline A ^a   Chilcott, Robert P ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Electroporation; Human skin absorption; In vitro; Iontophoresis; Physostigmine

Indexed keywords

PHYSOSTIGMINE;

ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG STABILITY; ELECTROPORATION; ELECTROSTIMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IONTOPHORESIS; NORMAL HUMAN; PRIORITY JOURNAL; SKIN; SKIN ABSORPTION; SKIN PENETRATION; TECHNIQUE; TRANSDERMAL DRUG ADMINISTRATION;

CHOLINESTERASE INHIBITORS; ELECTROPORATION; HUMANS; IONTOPHORESIS; PHYSOSTIGMINE; SKIN ABSORPTION;

EID: 0034632934     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(00)00242-X     Document Type: Article

References (29)

1. Marrs T.C., Maynard R.L., Sidell F.R. Chemical Warfare Agents - Toxicology and Treatment. 1996;John Wiley, Chichester. Chapter 4.
2. Leadbeater L. When all else fails [antidotes to chemical agents for troops]. Chem. Britain. 24:1988;683-688.
3. Hartvig P., Wiklund L., Lindstrom B. Pharmacokinetics of physostigmine after intravenous, intramuscular and subcutaneous administration in surgical patients. Acta Anaesthesiol. Scand. 30:1986;177-182.
4. Pardo A., Shiri Y., Cohen S. Percutaneous absorption of physostigmine: optimisation of delivery from a binary solvent by thermodynamic control. J. Pharm. Sci. 79:1990;573-578.
5. Walter K., Muller M., Barkworth M.F., Nieciecki A.V., Stanislaus F. Pharmacokinetics of physostigmine in man following a single application of a transdermal system. Br. J. Clin. Pharmacol. 39:1995;59-63.
6. Wetherell J.R. Continuous administration of low dose rates of physostigmine and hyoscine to guinea-pigs prevents the toxicity and reduces the incapacitation produced by soman poisoning. J. Pharm. Pharmacol. 46:1994;1023-1028.
7. Von Bredow J., Corcoran K., Maitland G., Kaminskis A., Adams N., Wade J. Efficacy evaluation of physostigmine and anticholinergic adjuncts as a pretreatment for nerve agent intoxication. Fundam. Appl. Toxicol. 17:1991;782-789.
8. Guy R.H. Current status and future prospects of transdermal drug delivery. Pharm. Res. 13:1996;1765-1769.
9. Garrison J. Iontophoresis: an alternative drug-delivery system. Med. Dev. Tech. 9:1998;32-36.
10. Banga A.K., Bose S., Ghosh T.K. Iontophoresis and electroporation: comparisons and contrasts. Int. J. Pharm. 179:1999;1-19.
11. Singh P., Maibach H.I. Iontophoresis: an alternative to the use of carriers in cutaneous drug delivery. Adv. Drug Del. Rev. 18:1996;379-394.
12. Vanbever R., Leroy M., Preat V. Transdermal permeation of neutral molecules by skin electroporation. J. Control. Release. 54:1998;243-250.
13. Weaver J.C., Vaughan T.E., Chizmadzhev Y. Theory of electrical creation of aqueous pathways across skin transport barriers. Adv. Drug Del. Rev. 35:1999;21-39.
14. D'Emanuele A., Staniforth J.N. An electrically modulated drug delivery device III. Factors affecting drug stability during electrophoresis. Pharm. Res. 9:1992;312-315.
15. Kalia Y.N., Nonato L.B., Guy R.H. The effect of iontophoresis on skin barrier integrity: non-invasive evaluation by impedance spectroscopy and transepidermal water loss. Pharm. Res. 13:1996;957-961.
16. Kligman A.M., Christophers E. Preparation of isolated sheets of human stratum corneum. Arch. Dermatol. 88:1963;70-73.
17. Chilcott R.P., Jenner J., Taylor C., Rice P. A rapid technique to identify structurally non-viable epidermal membranes during in vitro percutaneous penetration studies. Hum. Exp. Toxicol. 15:1996;161.
18. Chilcott R.P., Jenner J., Hotchkiss S.A.M. Transepidermal water loss and human skin permeability in vitro. Brain K.R., Walters K.A. Perspectives in Percutaneous Penetration. 1998;STS Publishing, Cardiff. In press.
19. Hemsworth B.A., West G.B. Anticholinesterase activity of some degradation products of physostigmine. J. Pharm. Sci. 59:1970;118-120.
20. Hsu E.S., Block L.H. Anionic gels as vehicles for electrically-modulated drug delivery. 1. Solvent and drug transport phenomena. Pharm. Res. 13:1996;1865-1870.
21. Fang J.Y., Huang Y.B., Wu P.C., Tsai Y.H. Transdermal iontophoresis of sodium nonivamide acetate II. Optimisation and evaluation on solutions and gels. Int. J. Pharm. 145:1996;175-186.
22. Oh S.Y., Jeong S.Y., Park T.G., Lee J.H. Enhanced transdermal delivery of AZT (Zidovudine) using iontophoresis and penetration enhancers. J. Control. Release. 51:1998;161-168.
23. Panus P.C., Campbell J., Kulkarni S.B., Herrick R.T., Ravis W.R., Banga A.K. Transdermal iontophoretic delivery of ketoprofen through human cadaver skin and in humans. J. Control. Release. 44:1997;113-121.
24. Pardo A., Shiri Y., Cohen S. Kinetics of transdermal penetration of an organic ion pair: physostigmine salicylate. J. Pharm. Sci. 81:1992;990-995.
25. Fang J.Y., Huang Y.-B., Wu P.-C., Tsai Y.-H. Transdermal iontophoresis of sodium nonivamide acetate I. Consideration of electrical and chemical factors. Int. J. Pharm. 143:1996;47-58.
26. Prausnitz M.R. A practical assessment of transdermal drug delivery by skin electroporation. Adv. Drug Del. Rev. 35:1999;61-76.
27. Pikal M.J. The role of electro-osmotic flow in transdermal iontophoresis. Adv. Drug Del. Rev. 9:1992;201-237.
28. Phipps J.B., Padmanabhan R.V., Lattin G.A. Iontophoretic delivery of model inorganic and drug ions. J. Pharm. Sci. 78:1989;365-369.
29. Jenner J., Saleem A., Swanston D. Transdermal delivery of physostigmine. A pretreatment against organophosphate poisoning. J. Pharm. Pharmacol. 47:1995;206-212.